



Institut national  
de la santé et de la recherche médicale

Paris, 19 April 2016

## Press release

### The origin of heart dysfunctions in myotonic dystrophy identified

**An international team, including researchers in France at Inserm, CNRS and the University of Strasbourg, brought together at IGBMC<sup>1</sup> is lifting the veil on the molecular mechanisms causing heart dysfunctions in myotonic dystrophy, a genetic disease affecting one person in 8,000. This new study, published this week in [Nature Communications](#), could contribute to discovering a treatment.**

Myotonic dystrophy, also known as Steinert disease, is the commonest adult form of muscular dystrophy. Patients affected by this genetic condition suffer from wasting of skeletal muscles as well as arrhythmia and other cardiac dysfunctions. This is a particularly debilitating disease, for which there is currently no treatment.

Myotonic dystrophy is due to a mutation leading to the expression of RNA containing long repetitive sequences of the CUG trinucleotide. These mutated RNAs accumulate and alter regulation of alternative splicing<sup>2</sup> of numerous genes. Despite the significance of work already done on this disease, many points remain to be elucidated. This is true for the origin of arrhythmia and other cardiac dysfunctions, which represent the second most common cause of death in this disease.

In this new study, researchers have identified new splicing alterations in messenger RNA from heart samples of affected patients. Among these many alterations, biologists have established that those relating to the cardiac sodium channel (SCN5A) were fundamental to understanding the cardiac dysfunctions of these patients.


Scientists there clarified the molecular mechanisms leading to the alteration of SCN5A in these patients. Collaboration with Denis Furling's team at the Institut de Myologie in Paris has enabled these cardiac alterations to be reproduced in a mouse model.

"The next step would be to see if, by restoring correct splicing of SCN5A, we can also successfully restore normal heart function", explains Nicolas Charlet-Berguerand, Inserm Research Director, who coordinated this work. The researchers are hoping that this breakthrough will give a fresh boost to research into this rare disease.

<sup>1</sup> Institute of Genetics and Molecular and Cellular Biology (Inserm/CNRS/University of Strasbourg)

<sup>2</sup> In eukaryotes, this is a process by which RNA transcribed from a gene can undergo different cutting and splicing steps leading to the loss of various regions. This process enables proteins having distinct properties to be produced from the same gene.

To find out more:



Alternative splicing model of the cardiac sodium channel (SCN5A) in myotonic dystrophy. Source: Inserm/IGBMC

*This work was financed by the French Myopathy Association (AFM), the European research council (ERC), the European E-rare programme (ANR), Inserm and Labex-INRT (ANR).*

## Sources

### Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy

Fernande Freyermuth<sup>1,\*</sup>, Frederique Rau<sup>2,\*</sup>, Yosuke Kokunai<sup>3</sup>, Thomas Linke<sup>4</sup>, Chantal Sellier<sup>1</sup>, Masayuki Nakamori<sup>3</sup>, Yoshihiro Kino<sup>5</sup>, Ludovic Arandel<sup>2</sup>, Arnaud Jollet<sup>2</sup>, Christelle Thibault<sup>1</sup>, Muriel Philipps<sup>1</sup>, Serge Vicaire<sup>1</sup>, Bernard Jost<sup>1</sup>, Bjarne Udd<sup>6,7,8</sup>, John W. Day<sup>9</sup>, Denis Duboc<sup>10</sup>, Karim Wahbi<sup>10</sup>, Tsuyoshi Matsumura<sup>11</sup>, Harutoshi Fujimura<sup>11</sup>, Hideki Mochizuki<sup>3</sup>, Francis Deryckere<sup>12</sup>, Takashi Kimura<sup>13</sup>, Nobuyuki Nukina<sup>14</sup>, Shoichi Ishiura<sup>15</sup>, Vincent Lacroix<sup>16</sup>, Amandine Campan Fournier<sup>17</sup>, Vincent Navratil<sup>18</sup>, Emilie Chautard<sup>19</sup>, Didier Auboeuf<sup>19</sup>, Minoru Horie<sup>20</sup>, Keiji Imoto<sup>21</sup>, Kuang-Yung Lee<sup>22</sup>, Maurice S. Swanson<sup>23</sup>, Adolfo Lopez de Munain<sup>24</sup>, Shin Inada<sup>25</sup>, Hideki Itoh<sup>20</sup>, Kazuo Nakazawa<sup>25</sup>, Takashi Ashihara<sup>20</sup>, Eric Wang<sup>23</sup>, Thomas Zimmer<sup>4</sup>, Denis Furling<sup>2</sup>, Masanori P. Takahashi<sup>3</sup> & Nicolas Charlet-Berguerand<sup>1</sup>

<sup>1</sup> Department of Translational medicine and neurogenetics, IGBMC, CNRS UMR7104, INSERM U964, Université de Strasbourg, Illkirch 67400, France.

2 Sorbonne Universités UPMC Univ Paris 06, Inserm, CNRS, Centre de Recherche en Myologie UMRS974/FRE3617, Institut de Myologie, GH Pitié-Salpêtrière, Paris 75013, France.  
3 Department of Neurology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.  
4 Department of Physiology, Friedrich Schiller University Hospital, Jena 07743, Germany.  
5 Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, Kiyose 205-8588, Japan.  
6 Neuromuscular Research Center, Tampere University and University Hospital, Tampere 33520, Finland.  
7 Department of Medical Genetics, Folkhalsan Institute of Genetics, Helsinki University, Helsinki 00250, Finland.  
8 Department of Neurology, Vaasa Central Hospital, Vaasa 65130, Finland.  
9 Department of Neurology, Stanford University, Stanford, California 94304, USA.  
10 Service de Cardiologie, Université Paris-Descartes, Hôpital Cochin, AP-HP, Paris 75014, France.  
11 Department of Neurology, Toneyama National Hospital, Toyonaka 560-8552, Japan.  
12 CNRS UMR7175, Ecole Supérieure de Biotechnologies de Strasbourg, Illkirch 67400, France.  
13 Division of Neurology, Hyogo Medical College, Nishinomiya 663-8501, Japan.  
14 Laboratory of Structural Neuropathology, Doshisha University Graduate School of Brain Science, Kyoto 610-0394, Japan.  
15 Graduate School of Arts and Sciences, University of Tokyo, Tokyo 153-8902, Japan.  
16 Université Lyon 1, CNRS, UMR5558 LBBE, Villeurbanne 69622, France.  
17 Hospices civils de Lyon, Laboratoire de cytogénétique constitutionnelle, Bron 69500, France.  
18 Pole Rhône Alpes de Bio-informatique, Université Lyon 1, Bâtiment Gregor Mendel, Villeurbanne 69100, France.  
19 Centre de Recherche en Cancérologie de Lyon, Lyon 69373, France.  
20 Department of Cardiovascular and Respiratory Medicine, Shiga Medical University, Otsu 520-2192, Japan.  
21 Department of Information Physiology, National Institute for Physiological Sciences, Okazaki 444-8585, Japan.  
22 Department of Neurology, Chang Gung Memorial Hospital, Keelung 20401, Taiwan.  
23 Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of Medicine, Gainesville, Florida 32610, USA.  
24 Department of Neurology, Hospital Universitario DONOSTIA, Neuroscience Area, Institute Biodonostia CIBERNED and University of Basque Country UPV-EHU, San Sebastian 20014, Spain.  
25 Laboratory of Biomedical Sciences and Information Management, National Cerebral and Cardiovascular Center Research Institute, Osaka 565-8565, Japan. \* These authors contributed equally to the work  
[Nature Communications](#), April 2016

## Research contact

### Nicolas Charlet- Berguerand

Inserm Research Director

Institute of Genetics and Molecular and Cellular Biology (IGBMC)

[ncharlet@igbmc.fr](mailto:ncharlet@igbmc.fr)

Tel.: +33 (0)3 88 65 33 09

## Press contact

[presse@inserm.fr](mailto:presse@inserm.fr)



Access the [Inserm press room](#)